Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death, treatment information, TNM staging, tumor size, location, etc. DNA sequencing was performed on 300 collected esophageal cancer samples, divided into mutant and wild-type types. Perform immunohistochemistry on tissue slices and observe the expression of P53 mutant protein. ELISA was used to study the expression of serum anti-P53 autoantibodies. Process these data and use them to classify subtypes of esophageal cancer. Associate each subtype with clinical information, analyze the characteristics of each subtype, such as the multidimensional features of P53 and treatment correlation analysis, and the correlation between P53 multidimensional features and survival.
Inclusion Criteria:
Exclusion Criteria:
Hangzhou, Zhejiang 310022, China
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring
p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer
Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer
A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients
The Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan